Head and Neck Flashcards

1
Q

Most common histology

A
squamous cell
(alternate etiology suggest salivary or thyroid origin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Incidence of new diagnosis,
Sex,
Age

A

3%,
M>F (3:1),
>60 (except HPV: 40-60)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Enviornmental Risk Factors

A
  1. Alcohol or Tobacco (if combine 100 fold increase)
  2. EBV (nasopharyngeal: endemic in southern China and Hong Kong)
  3. HPV (70% oropharyngeal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Premalignant Lesions

A

Leukoplakia: fixed white patches
Erythroplakia: red patches; often with epithelial dysplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Key Molecular Abnormalities

A

p53 (poor prognosis, usually w/ Alcohol & Tobacco)
p16 inactivation
EGFR overexpression
CCND1 over expression
HPV: E6, E7 viral protein: inhibits tumor suppressors ie. p53, Rb
EBV: LMP1 protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Big Picture:

A

multimodality approach allows for cure even in locally advanced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

In addition to cure we strive for:

A

organ preservation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment baskets:

A
  • Early Stage (stage I-II; not high risk): single modality: surgery or RT
  • Locally Advanced (stage III-IVB): surgery with adjuvant radiation +/- chemo or definitive chemoradiation
  • Metastatic: combination chemo (ECOG1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are high risk features in early stage that warrant adjuvant therapy?

A
  • extracapsular extension
  • vascular embolism
  • perineural invasion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When is adjuvant radiation + chemo preferred?

A

> 2 positive nodes
+ surgical margins (consider re-surgery first)
+ extracapsular extension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When is definitive chemoradiation preferred?

A
nonsurgical disease (Adelstein JCO 2003)
larynx preservation (Forastiere NEJM 2003)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are 6 primary sites of origin for SCC of Head and Neck?

A
Oral Cavity
Oropharynx
Nasal Cavity
Nasopharynx
Hypophaynx
Larynx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Components of oral cavity?

A

lips, alveolar ridge, hard palate, buccal mucosa, anterior 2/3 tongue, floor of mouth, retromolar trigone (7)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Components of Oropharynx?

A

palatine tonsils, posterior 1/3 of tongue, vallecula, lingual tonsil, midportion of posterior pharyngeal wall, interior surface of soft palate, uvula (7)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Components of Nasal Cavity?

A

Nasal septum, mucosa of nasal cavity; superior, middle and inferior turbinates (3)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Components of Nasopharynx?

A

superior surface of soft palate, upper portion of posterior pharyngeal wall above level of uvula (2)

17
Q

Components of Hypopharynx?

A

Postcricoid area, pyriform sinus (2)

18
Q

Components of Larynx?

A

Supraglottis: supra and infrahyoid epiglottis, aryeepiglottic folds, arytenoids, falso crods
Glottis: tru vocal cords, anterior and posterior commissures, region 1cm below true vocal cords
Subglottis: from 1cm below true vocal cords to cervical trachea

19
Q

Overview of stages in SCC in H&N?

A
  • early (I-II)
  • locally advanced but potentially curable (III-IVB)
  • uncurable (IVC)
20
Q

Features of early stage H&N cancer?

A

Tumor

21
Q

Features of locally advanced disease in H&N cancer?

A

extensive local involvement and/or lymph node involvement

22
Q

Features of incurable

A

distant metastasis

23
Q

Preffered surgical margins in H&N cancer?

A

> 5mm

24
Q

Preffered XRT modality (why?) and standard?

A

IMRT (reduced xerostomia and optimize targeting), standard id EBRT 66-70 Gy

25
Q

Short and long term side effects of XRT in H&N?

A

fatigue, xerostomia, 2ndary malignancies (sarcomas)

26
Q

Preffered agent in locally advanced H&N cancer for concurrent chemoXRT or adjuvant chemo if margins + or extracapsular extension (?

A

Cisplatin

  • CRT: (RTOG 91-11 JCO 2013)
  • adjuvant: increase DFS & OS (Bernier NEJM 2004, Cooper NEJM 2004)
27
Q

Alternatives to cisplatin in advanced H&N disease?

A
  • Carbo + 5FU for chemoXRT (JCO 2004)

- Cetuximab for chemoXRT (Bonner, NEJM 2006)

28
Q

Recommended regimen for metastatic H&N cancer? (associated trial?)

A

Platinum doublet + cetuximab (EXTREME NEJM 2008)

- cis or carbo + taxanxe or 5FU

29
Q

Is there a role for induction therapy in H&N cancer? (common regimen, evidence?)

A

No

  • TPF: docetaxel, cisplatin and 5-Fu
  • Paradigm (Lancet 2013) and Decide trials (JCO 2012)
30
Q

Is there a role for reirradiation?

A

yes